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Nufﬁeld Department of Medicine, and Peter Medawar Building, University of Oxford, South Parks Rd, Oxford, UKBackground & Aims:With the increasing prevalence of liver dis-
ease worldwide, there is an urgent clinical need for reliable meth-
ods to diagnose and stage liver pathology. Liver biopsy, the
current gold standard, is invasive and limited by sampling and
observer dependent variability. In this study, we aimed to assess
the diagnostic accuracy of a novel magnetic resonance protocol
for liver tissue characterisation.
Methods:We conducted a prospective study comparing our
magnetic resonance technique against liver biopsy. The
individual components of the scanning protocol were T1 map-
ping, proton spectroscopy and T2⁄ mapping, which quantiﬁed
liver ﬁbrosis, steatosis and haemosiderosis, respectively. Unse-
lected adult patients referred for liver biopsy as part of their rou-
tine care were recruited. Scans performed prior to liver biopsy
were analysed by physicians blinded to the histology results.
The associations between magnetic resonance and histology vari-
ables were assessed. Receiver-operating characteristic analyses
were also carried out.Journal of Hepatology 20
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ating Characteristic Curve.Results: Paired magnetic resonance and biopsy data were
obtained in 79 patients. Magnetic resonance measures correlated
strongly with histology (rs = 0.68 p <0.0001 for ﬁbrosis; rs = 0.89
p <0.001 for steatosis; rs = 0.69 p <0.0001 for haemosiderosis).
The area under the receiver operating characteristic curve was
0.94, 0.93, and 0.94 for the diagnosis of any degree of ﬁbrosis, ste-
atosis and haemosiderosis respectively.
Conclusion: The novel scanning method described here provides
high diagnostic accuracy for the assessment of liver ﬁbrosis, ste-
atosis and haemosiderosis and could potentially replace liver
biopsy for many indications. This is the ﬁrst demonstration of a
non-invasive test to differentiate early stages of ﬁbrosis from nor-
mal liver.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Over 10% of adults in Western populations have some degree of
liver disease [1,2]. The increasing prevalence of obesity, alco-
hol-related liver disease, and viral hepatitis has led to an epi-
demic of progressive liver disease and cirrhosis.
There is a pressing need for a reliable diagnostic tool to iden-
tify early stages of liver disease and to target therapies to those
patients who may beneﬁt from these (e.g., antiviral therapy in
progressive hepatitis C). Liver biopsy, the current ‘gold-standard’,
carries a signiﬁcant risk of serious bleeding complications and is
costly. Furthermore, a biopsy allows examination of only 0.002%
of the liver, and there is great intra- and inter-observer variability
in histological interpretation, such that many argue liver biopsy is
not a true gold-standard [3]. Consequently, there is a real clinical
need for non-invasive tools to evaluate and monitor liver disease.
Transient elastography, which in Europe is increasingly used
in clinical practice, can only accurately diagnose cirrhosis and14 vol. 60 j 69–77
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has limited utility in obesity [4]. Tests based on serum markers
have been mainly studied in preselected populations – when
applied to mixed cohorts they were found to lack sensitivity, par-
ticularly in differentiating early stages of disease [5].
We present a proof-of-principle study, describing a novel
magnetic resonance (MR) protocol that can be performed without
intra-venous contrast on existing scanners. MR methods are ide-
ally suited for tissue characterisation as they can sample the
entire liver quickly, and are safe, reproducible, and widely avail-
able. Using multiparametric MR, we were able to objectively
quantify hepatic ﬁbrosis, steatosis and haemosiderosis, an impor-
tant step towards a safer alternative to liver biopsy.Patients and methods
Study design and population
This was a prospective, comparative, non-randomised, study of a new diagnostic
MR method to evaluate liver disease. The designated reference standard was his-
tological assessment of liver ﬁbrosis, steatosis and haemosiderosis. From March
2011 to May 2013, we invited all patients referred for liver biopsy at two UK
study centres (Oxford and Reading), to take part, except for those with contrain-
dications to MR scanning. 90 patients consented to participate. Two were unable
to undergo MR investigation due to claustrophobia, and nine did not have liver
biopsy within six months of consent, leaving 79 patients for the ﬁnal analysis
(baseline characteristics in Table 1). The study protocol is shown in Fig. 1. Refer-
ence MR data were also collected from seven healthy volunteers with no known
liver disease and BMI <25 kg/m2 (Supplementary Table 1).
MR operators were blinded to the indication for liver biopsy and to the
patients’ clinical details. MR data were analysed prior to histological reporting.
The histopathologists were blinded to the MR data. Histological measures of ste-
atosis, ﬁbrosis and haemosiderosis were then compared to the non-invasive MR
measures of the same parameters.
The study protocol conforms to the ethical guidelines of the 1975 Declaration
of Helsinki, and was approved by the institutional research departments and the
National Research Ethics Service (11/H0504/2). The study was registered with
clinicaltrials.gov (NCT01543646). All patients and volunteers gave written
informed consent.
Histological interpretation of liver biopsy samples
The median biopsy length after processing was 20 mm (IQR 16-30) and each
biopsy contained a median of 10 (IQR 8-15) portal tracts. All biopsies were
included in the ﬁnal analysis. As there is considerable inter-observer variation
in reporting of liver biopsy [6,7], samples from 65 patients were assessed by three
independent expert liver histopathologists (LMW, DWD, & KAF).
All samples were assessed for ﬁbrosis by Ishak stage (F0–F6) [8]. For this
study mild ﬁbrosis was deﬁned as Ishak F1–F2, moderate ﬁbrosis as Ishak F3–
F4, and severe ﬁbrosis as IshakPF5. In cases where the biopsy showed steatohep-
atitis (n = 36), subgroup analysis was performed comparing MR data against the
NAFLD Fibrosis Stage (F0–F4) [9]. In 54 biopsy samples available for this, collagen
proportionate area (CPA) was also assessed by analysis of digital images using
ImageJ (see Supplementary Methods for details).
Hepatic lipid content was measured by determining the percentage of
hepatocytes with visible lipid vesicles. This was graded as 0 (<5%), 1 (5- <33%),
2 (33- <66%) and 3 (>66%), as described by Brunt [10].
Stainable iron was estimated using a Perls’ histochemical stain and semi-
quantiﬁed using a ﬁve tier grading system (0: no haemosiderosis to 4: severe
haemosiderosis) [11].
Inter-observer variability between the three histology measurements for ste-
atosis, ﬁbrosis and haemosiderosis was determined using weighted kappa statis-
tics. The ﬁnal histology scores for all 79 patients were determined by consensus
agreement.
Magnetic resonance protocol
All MR scans were performed in Oxford with the patient lying supine in a 3 Tesla
system (Tim Trio, Siemens Healthcare, Germany). Patients attended for their70 Journal of Hepatology 20scans having fasted for at least 4 h. The average scan time for this protocol was
23 min. For the assessment of repeatability, T1 and T2⁄ maps were acquired in
ten volunteers on two occasions within a week. The mean coefﬁcients of variance
(CoV) for T1, T2⁄, and cT1 (see below) were calculated. 1H MRS using this protocol
has previously been determined to have a CoV of 4.8% [12]. A more detailed
description of the MRI methods and MR acquisition parameters is included in
the Supplementary Methods.Fibrosis (extracellular water) imaging
A T1 relaxation time map was acquired using the shortened Modiﬁed Look
Locker Inversion (shMOLLI) recovery sequence in a transverse plane of the liver
[13]. This sequence samples the T1 recovery curve using single-shot balanced
steady state free precession acquisitions. There is a quality assurance compo-
nent – each acquisition generates an R2 map for the ﬁt of signal intensity to
the exponential recovery curve [14]. For this study, an image was only
considered for interpretation if the R2 was P99% which was the case in all
patients.
Hepatic steatosis measurement with 1H MRS
Hepatic lipid content (HLC) can be quantiﬁed using localised cardiac-triggered
proton spectroscopy [15]. HLC as a percentage of the liver water content using
1H MRS was measured with water suppression in an 8 cm3 voxel, avoiding vascu-
lar and biliary structures.Iron content imaging
A multi-gradient-echo acquisition was used to calculate a T2⁄ map of the liver
in a single plane with a slice thickness of 3 mm. Two patients had iron over-
load too severe to be accurately quantiﬁed using this protocol, with T2⁄ <2 ms
in each case.MR image analysis
MRI – Data were analysed by physicians blinded to the clinical information, using
software tools available on the scanner console. For each patient, a single Region
of Interest (ROI) was selected on the transverse T1 and T2⁄ maps, corresponding
to segment 8 of the liver, from where most percutaneous biopsies are taken. The
tissue volume assessed in each ROI is between 25–30 ml (compared to 0.05–
0.08 ml in a liver biopsy). Each ROI contained between 100–200 pixels each,
returning a T1 and T2⁄ value for the liver area corresponding to that pixel. Mean
T1 and T2⁄ values were recorded for each ROI and used in the ﬁnal analysis (see
also Supplementary Fig. 1).
MRS data were analysed ofﬂine, using AMARES in the jMRUI package and cus-
tomised software running within MATLAB 2010b, as previously described.15 HLC
was expressed as % of water signal.Correction for iron
The T1 measurements in this work aim to detect the presence of elevated
extracellular water, reﬂected in an increased T1 value. However, the presence
of excess iron competes with this effect, reducing T1. Further, the shMOLLI
method is affected by T2 and T2⁄, which are reduced with elevated iron levels.
In an interim analysis of the data, we found that a substantial proportion of
patients had elevated liver iron levels, and we therefore developed a method
to correct for this confounder. Elevated iron concentrations can be determined
accurately from the T2⁄ maps. The T1 measurements provide an estimate of
the extracellular water content, and thus it is necessary to remove the bias
introduced by the elevated iron. To do this, the shMOLLI sequence was mod-
elled using a Bloch simulation for varying extracellular ﬂuid and iron
concentrations, and a correction algorithm was generated [16]. This was then
used to remove the effects of elevated iron from the T1 measurements, yield-
ing an ‘iron-corrected T1’ (cT1; the T1 that would be measured using the
shMOLLI sequence at a normal iron level; 1.3 mg/g) for the chosen ROI.
Iron-corrected T1 could not be estimated in two patients with severe iron
overload (T2⁄ <2ms), leaving 77 patients with paired MR and histology data
for ﬁbrosis assessment.14 vol. 60 j 69–77
Table 1. Baseline characteristics of the 79 patients included in the ﬁnal analysis.
Median/mean IQR/SD Min value Max value
Male : Female 58 : 21
Age (yr) - mean ± SD 50 13 16 78
Anthropometric data
Weight (kg) 79 19 45 128
BMI (kg/m2) 26.9 6.4 17.1 45.4
Liver enzymes
Bilirubin (IU/L) 10 9 4 88
ALT (IU/L) 61 71 14 3930
AST (IU/L) 50 42 16 3546
GGT (IU/L) 85 178 12 900
Alk phosphatase (IU/L) 207 146 112 1497
Total cholesterol (mmol/L) 4.4 1.6 2.2 8.4
Triglycerides (mmol/L) 1.1 0.8 0.4 7.9
HDL-cholesterol (mmol/L) 1.2 0.5 0.5 2.6
Glucose (mmol/L) 5·0 1·2 3·7 19
Albumin (g/L) 45 3 28 54
C-reactive protein (mg/L) 2.6 7.0 <0.5 >156
Haematological indices
Haemoglobin (g/dl) - mean ± SD 15.0 1.9 9.5 18.6
White cell count (x 109/L) - mean ± SD 6.8 2.0 3.0 11.4
Platelets (x 109/L) 184 100 23 574
Prothrombin time (s) 14.0 1.9 11.5 18.0
Ferritin 256 441 3.9 4511
N %
0 7 8.9
1 16 20.3
2 25 31.6
3 10 12.7
4 3 3.8
5 4 5.1
6 14 17.7
Final diagnosis after biopsy
Viral hepatitis 31 39.2 5 had coexistent SH
Steatohepatitis (alcoholic and non-alcoholic) 31 39.2 2 patients had coexistent disease (1 A1AT, 1 PBC)
Iron overload 2 2.5
PSC/PBC 6 7.6 3 PSC/3 PBC
Normal 2 2.5
Other 7 8.9
Ishak fibrosis stage
Serum metabolic profile
Values shown as median with IQR unless stated otherwise. Shapiro-Wilk test for normality used.
SH, steatohepatitis; A1AT, Alpha-1-Antitrypsin Deﬁciency; PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis.
JOURNAL OF HEPATOLOGYStatistical analysis
Descriptive statistics were used to summarise subject characteristics. Summary
data were calculated for different stages of ﬁbrosis, steatosis and the presence
or absence of haemosiderosis. ANOVA with Bonferroni’s correction for multiple
comparisons was used to determine signiﬁcant differences between mean valuesJournal of Hepatology 20for categories among normally-distributed continuous variables. Normality was
determined by use of the Shapiro-Wilk test. Spearman (rs), and Pearson’s correla-
tions (r) were calculated to test associations between categorical and continuous
variables, respectively. To determine the diagnostic utility of MR for assessing
liver ﬁbrosis, receiver-operating characteristic analyses were carried out using
GraphPad Prism 5 software.14 vol. 60 j 69–77 71
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Fig. 1. Study protocol with examples of normal and abnormal MR measurements. The images show MR T1 maps from patients with no liver ﬁbrosis on biopsy (A) and
cirrhosis (B) and MR T2⁄ maps from patients with negative Perls’ stain for iron (C) and grade 1 haemosiderosis (D). T1 and T2⁄ measured in milliseconds are translated into
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Fig. 2. cT1 values in 77 patients and 7 healthy volunteers (presumed with no
ﬁbrosis) plotted against their biopsy proven ﬁbrosis stage. Iron-corrected T1
(cT1) correlates with the degree of ﬁbrosis in all subjects (rs = 0.68, p <0.0001, 95%
CI 0.54–0.78). Mean ± SD cT1 for each group was as follows: healthy volunteers
717 ± 48 ms, no ﬁbrosis 750 ± 42 ms (those two are grouped as ‘‘normal liver’’),
mild ﬁbrosis 870 ± 104 ms, moderate 873 ± 63 ms, and severe 1025 ± 102 ms.
ANOVA with Bonferroni’s correction showed signiﬁcant differences (⁄⁄⁄) between
all groups apart from mild vs. moderate ﬁbrosis (n.s., not signiﬁcant; Table 2).
Liver biopsy patients are shown as red dots, and healthy volunteers as blue
squares.
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Results
Hepatic ﬁbrosis and T1 mapping
The mean corrected T1 for the 7 healthy volunteers was
717 ± 48 ms which was similar to the mean cT1 in patients with
no ﬁbrosis on liver biopsy (F0; n = 7; cT1 750 ± 42 ms; p = 0.20).
For all subjects cT1 strongly correlated with increasing liver
ﬁbrosis [cT1 vs. Ishak (n = 84): rs = 0.68, p <0.0001; Fig. 2 and
cT1 vs. CPA (n = 54): r = 0.54, p <0.0001]. Furthermore, there were
signiﬁcant differences in cT1 among all stages, except between
mild and moderate ﬁbrosis (Fig. 2 and Table 2).
In discriminating healthy volunteers and patients with no
ﬁbrosis on liver biopsy from those with any degree of ﬁbrosis
(IshakPF1), cT1 had an Area Under the Receiver Operating Char-
acteristic (AUROC) of 0.94 (p <0.0001, 95% CI 0.90–0.99), with a
sensitivity of 86% and a speciﬁcity of 93% at a threshold of
800 ms (Supplementary Fig. 4).
When the two main aetiologies were assessed separately, i.e.,
viral hepatitis (n = 31; rs = 0.76, p <0.0001) and steatohepatitis
(n = 36; rs = 0.62, p <0.0001), cT1 correlated closely with their
respective disease-speciﬁc ﬁbrosis scoring systems (Supplemen-
tary Fig. 5). There was also strong correlation with CPA [for viral
hepatitis (n = 18): r = 0.86, p <0.0001 and for steatohepatitis
(n = 22): r = 0.57, p = 0.0061]. Moreover, cT1 clearly identiﬁed
patients with ﬁbrosis (Viral hepatitis AUROC 0.92, p = 0.019,
95% CI 0.79–1.05; steatohepatitis AUROC 0.90, p = 0.0096, 95%
CI 0.79–1.01). Fig. 3 shows transverse MR T1 maps of four
patients with chronic viral hepatitis, and corresponding liver
biopsies. Increasing ﬁbrosis is reﬂected in a higher T1 graphically
on the colour scale, and can also be estimated quantitatively in
milliseconds as cT1.
Hepatic steatosis and 1H MRS
Rapid spectroscopy measurement of HLC correlated strongly with
semi-quantitative steatosis scores (Fig. 4; rs = 0.89, p <0.0001). In
distinguishing patients with a Brunt steatosis score of 0 from
those with scores P1, MRS had an AUROC of 0.93 (95% CI 0.87–
0.99, p <0.0001). MRS thresholds of 1.5% and 7.5% of the water
signal identiﬁed histologically visible steatosis (BruntP1; sensi-
tivity 85%, speciﬁcity 100%) and severe steatosis (Brunt >2; sensi-
tivity 100%, speciﬁcity 97%), respectively. There was strong
correlation with quantitative histology scores of steatosis and
very little variance of HLC in the left and right lobes of the liver
(Supplementary Fig. 6).Table 2. One Way Analysis of Variance (ANOVA) with Bonferroni’s correction for co
showing signiﬁcant differences between all groups except mild ﬁbrosis (F1–2) vs. m
Bonferroni’s multiple comparison test Mean 
difference
t
Normal liver (n = 14) vs. F1-2 (n = 40) -136.3 4.804
Normal liver (n = 14) vs. F3-4 (n = 13) -139.4 3.960
Normal liver (n = 14) vs. F5-6 (n = 17) -291.8 8.849
F1-2 (n = 40) vs. F3-4 (n = 13) -3.050 0.105
F1-2 (n = 40) vs. F5-6 (n = 17) -155.5 5.878
F3-4 (n = 13) vs. F5-6 (n = 17) -152.5 4.529
n.s., not signiﬁcant.
Journal of Hepatology 20Hepatic iron content and T2⁄
Hepatic iron content showed a strong negative correlation with
T2⁄ (rs = 0.69, p <0.0001; Fig. 4). In distinguishing patients with
stainable iron from those without, T2⁄ had an AUROC of 0.94 (95%
CI 0.87–1.00, p <0.0001). For the diagnosis of any degree of hae-
mosiderosis, a T2⁄ threshold of 12.5 ms had a sensitivity of 86%
and a speciﬁcity of 93%.
Inter-observer variance in histopathological assessment
Liver biopsies from 65 patients were independently reported by
three pathologists, blinded to the clinical data and previous path-
ological reports. There was good agreement for the assessment ofmparison between disease severity groups, for all subjects with cT1 (n = 84)
oderate ﬁbrosis (F3–4).
p value <0.05?
Summary 95% CI of difference
Yes *** -213.1 to -59.54
Yes *** -234.6 to -44.14
Yes *** -381.1 to -202.6
No n.s. -81.98 to 75.88
Yes *** -227.1 to -83.94
Yes *** -243.6 to -61.38
Significant
14 vol. 60 j 69–77 73
4
T1 (s)
0 1 2 3
F2
F3
F0cT1: 783 ms
cT1: 882 ms
cT1: 928 ms
F6cT1: 1071 ms
Fig. 3. Viral hepatitis ﬁbrosis staging with MR T1 mapping and iron-corrected
T1 measurements in the regions of interest. Examples of transverse liver MR T1
maps from 4 patients with viral hepatitis (left column). The white circles indicate
typical areas of interest corresponding to tissue volume of 25–30 ml, where the
T1 and T2⁄ would be measured in order to estimate cT1, which is included
for each patient. The corresponding liver biopsy slides stained with Sirius Red for
ﬁbrosis (Ishak F0–F6; magniﬁcation 4) for each patient are shown for
comparison (right column). The appearance of the MR T1 map and the
quantitative measure of ﬁbrosis (cT1), clearly correlate with the degree of
ﬁbrosis as assessed by the Ishak score.
Research Articlesteatosis (kappa = 0.72), but only modest agreement in the
assessment of ﬁbrosis (kappa = 0.58) and haemosiderosis
(kappa = 0.58), most notably in the classiﬁcation of mild and
moderate disease (Supplementary Table 2). The agreement
achieved here is better than in previously reported studies [6,7].74 Journal of Hepatology 20Repeatability of MR measures
The mean coefﬁcient of variance (CoV) over 10 normal volunteers
was 1.3% for T1 maps, 8.4% for T2⁄ maps and 1.8% for the com-
bined cT1 metric, showing good repeatability. 1H MRS CoV was
previously shown to be 4.8% [12].
Discussion
With the global epidemic of steatohepatitis (both alcoholic and
non-alcoholic), and the reported 450 million worldwide with
viral hepatitis, there is a pressing need for an accurate, quick
and simple diagnostic test to determine the type and degree of
liver disease. The new method of liver assessment by multipara-
metric MR imaging and spectroscopy described here provides
detailed non-invasive tissue characterisation of a large sample
of liver parenchyma, and can identify and quantify ﬁbrosis, stea-
tosis and iron content, quickly and safely, with a high degree of
sensitivity and speciﬁcity.
Our MR protocol objectively quantiﬁes biomarkers for ﬁbrosis,
steatosis and haemosiderosis, all of which are essential compo-
nents of the characterisation of liver tissue on biopsy. The assess-
ment of hepatic ﬁbrosis with this technique is especially strong
because it can differentiate those with any degree of ﬁbrosis from
those with normal livers and those with severe ﬁbrosis from
those with mild or moderate disease in an unselected patient
population, something that has not been shown previously.
Current alternative techniques for non-invasive ﬁbrosis measure-
ment have only been tested on pre-selected populations
[5,17–20]. Elastography (based on either ultrasound or MRI) is
limited in obese patients and subjects with ascites. Serum
markers of hepatic ﬁbrosis are sensitive, but not speciﬁc, and
have not been tested in general populations with coexisting
ﬁbrosis in other organs. Our T1 mapping method is unaffected
by the degree of adiposity or the presence of ascites, unlike
acoustic-based techniques such as elastography, and also has
the potential to demonstrate which parts of the liver are affected
or spared.
The earliest work suggesting the concept that T1 relates to the
degree of liver ﬁbrosis was reported in 1981 [21] but subsequent
studies failed to show any clear relationship [22,23]. Recently,
with the development of robust single breath-hold T1 mapping
techniques, interest in the ﬁeld has increased again [24,25]. How-
ever, these previous studies have limited clinical applicability, as
they did not assess iron and ﬁbrosis in an unselected population.
Crucially, the importance of iron-compensation in determining
the true relationship between T1 and ﬁbrosis has not been shown
before. Our study, for the ﬁrst time, suggests that MR T1 mapping
may be a practical method for ﬁbrosis assessment in nearly all-
comers (77/79 in our study) for liver biopsy.
Measurement of hepatic lipid content by MR methods has
been described before, based on 1H-MRS or Dixon-type MRI,
the current consensus being that MRS is the most accurate
method [26,27]. We thus opted for an MRS approach in our mul-
tiparametric protocol, and have further reﬁned existing MRS
methods by using rapid breath-hold spectroscopy. We have also
demonstrated that fat was fairly equally distributed in the liver
(Supplementary Fig. 2), as previously described [28].
The assessment of iron content with T2⁄-sensitive MR has
been used in clinical practice for the management of inherited14 vol. 60 j 69–77
0.1
1
0
10
20
30
40
0 1 2 3
10
100
Lo
g 1
0 H
LC
 a
s 
%
 o
f w
at
er
 s
ig
na
l 
T2
* (
m
s)
Histology steatosis grade
0 1 2 3 4
Haemosiderosis grade
A
B
Fig. 4. The assessment of hepatic steatosis with 1H MRS and hepatic
haemosiderosis with T2⁄ mapping. (A) There was a very strong correlation
between steatosis grade hepatic lipid content measured by 1H MRS (rs = 0.89,
p <0.0001). MRS thresholds of 1.5% and 7.5% steatosis respectively identiﬁed a
steatosis grade of P1 (sensitivity 80%, speciﬁcity 100%) and a steatosis grade of
>2 (sensitivity 100%, speciﬁcity 97%). (B) There was a strong negative correlation
between histological grading of iron deposition and T2⁄ (rs = 0.69, p <0.0001,
95% CI 0.79 to 0.55). A T2⁄ cut off at 12.5 ms identiﬁed any degree of
haemosiderosis with a sensitivity of 86% and a speciﬁcity of 93%.
JOURNAL OF HEPATOLOGYand acquired iron storage disorders [29], but has not been utilised
in a general population before. Our data conﬁrm previous ﬁnd-
ings of T2⁄ correlation with stainable iron levels on biopsy [30].
The real innovation our study brings is that all the above
information is generated from one 23 min MRI scan that can be
applied to a general patient population referred for liver biopsy,
and that the T1 ﬁbrosis measurement is made generally applica-
ble by an iron correction algorithm. In 51/77 (66%) of patients, a
correction of P20 ms in the measured T1 had to be made. Our
patient group was heterogeneous, and no category was excluded
from participation. It is clear from our analysis that this heteroge-
neity has impacted on the overall results as the correlations with
CPA are higher when different aetiologies are considered sepa-
rately (r = 0.54 for all patients, r = 0.57 for steatohepatitis and
r = 0.86 for viral hepatitis). Despite this, our results are generali-
sable to an adult population with suspected liver disease, and our
technique may prove of particular use in patients with coexisting
pathology, such as viral hepatitis and non-alcoholic steatohepati-
tis. Currently, there are separate histological scoring systems for
these pathologies. Consequently, interpretation and comparison
are difﬁcult, even before sampling and inter-observer variations
are considered. In contrast, the method presented here correctly
identiﬁed patients with both steatosis and ﬁbrosis, regardless of
aetiology, and is highly repeatable.Journal of Hepatology 20Future work
As a truly quantitative non-invasive technique for the character-
isation of liver tissue, this methodology has the potential for the
safe longitudinal assessment and prediction of disease progres-
sion and regression and/or response to therapy, without the need
for repeat liver biopsy. This has not been feasible in the past, and
opens up many possibilities for research and clinical use into new
therapeutic strategies for hepatic and metabolic conditions. For
example, the degree of liver damage caused by alcohol and die-
tary excess may be quantiﬁed over time providing a much safer
means to monitor alcohol related liver disease and non-alcoholic
steatohepatitis. The method will also enable studies to assess
regional variations throughout the liver, which is of particular
interest in conditions with patchy ﬁbrosis, such as primary scle-
rosing cholangitis and primary biliary cirrhosis. Future studies
will have to assess the value of this method in a multicentre for-
mat and also determine whether MRI assessment of liver ﬁbrosis
by cT1 measurements predicts patient outcome. The results of
these studies will determine whether it is possible for multipara-
metric MR assessment of the liver to eventually replace liver
biopsy for the staging of ﬁbrosis and grading of steatosis and
haemosiderosis.Study limitations
This was a study of unselected patients attending for liver biopsy,
which showed clear separation between all groups except
between mild vs. moderate ﬁbrosis. Given its small size, it only
demonstrates initial proof-of-principle. Limitations include fac-
tors related to the MR technique and to the use of biopsy as a ref-
erence standard.
MR methodological limitations include the fact that two of
our patients had massive haemosiderosis, with T2⁄ <2 ms, which
did not allow for the estimation of cT1 to determine the degree of
ﬁbrosis. Our method worked correctly in 77/79 patients and, in
practical terms, T2⁄ values of <2 ms immediately indicate the
presence of marked haemosiderosis, but still requiring histologi-
cal assessment of ﬁbrosis. In addition cT1 is a marker of extracel-
lular water content, which can rise with oedema in the acute
setting or ﬁbrosis in chronic illness, or both if there is acute insult
to a ﬁbrotic liver. However, interpretation based on the clinical
picture, history, and routine serum biochemistry from the patient
can guide the observer towards the correct choice between acute
and/or chronic liver disease. Our MR maps for T1 and T2⁄ covered
one large transverse slice, but may have missed patchy disease
occurring in other planes. Further reﬁnement to obtain whole-
liver analysis may address this, but will have to be balanced
against the cost-effectiveness of longer acquisition times. Finally
applicability at other ﬁeld strengths, in particular 1.5T, need to be
demonstrated.
Percutaneous liver biopsy is not an ideal reference standard
for ﬁbrosis, steatosis or haemosiderosis. We have included all
biopsies in the ﬁnal analysis irrespective of their length or num-
ber of portal tracts and this may have affected the accuracy of
histological assessment. We assessed inter-observer variance by
comparing scores from three blinded pathologists. Although their
agreement was in keeping with previous published studies [6],
trivariate weighted kappa of 0.58 for ﬁbrosis assessment suggests
only moderate concordance. For uniformity, the Ishak score was
used to evaluate ﬁbrosis in all patients irrespective of their ﬁnal14 vol. 60 j 69–77 75
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diagnosis, including patients with coexistent disease. This may
have underestimated the burden of disease due to pericellular
ﬁbrosis, particularly in patients with steatohepatitis. As we
designed a study for all-comers for liver biopsy, patients with
vascular liver pathology (e.g., hepatic venous outﬂow obstruc-
tion) or acute hepatitis in patients with chronic liver disease,
who would be expected to have higher cT1 due to liver conges-
tion or inﬂammation, were also included. In this situation, cT1
likely overestimates the degree of chronic ﬁbrosis. Furthermore,
the liver volume (0.05–0.08 ml) for histological analysis of ﬁbro-
sis was nearly 3 orders of magnitude smaller than the volume for
MR analysis (25–30 ml). Thus, even a perfect non-invasive tech-
nique would not necessarily be expected to achieve a higher cor-
relation with histology than that observed here, and the
correlation coefﬁcient observed between MRI and biopsy esti-
mates of ﬁbrosis (rs = 0.68) is remarkably high in light of these
limitations.
Larger studies will have to assess the value of this new
method for distinguishing mild from moderate ﬁbrosis for sub-
types of chronic liver disease, and these may require more
selected populations.Conclusions
We describe a new, accurate and safe method to characterise the
severity and type of liver disease, thus aiding diagnosis and stag-
ing. The non-invasive data generated closely correlate with liver
biopsy measurements of steatosis, haemosiderosis and ﬁbrosis, as
demonstrated in this prospective, blinded study in an unselected
liver biopsy population. MR is increasingly accessible, and this
technique should now be validated in clinical multicentre studies
to further deﬁne its clinical use for assessing chronic liver disease
in adults and children.Financial support
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